Melissa Paoloni

4.6k total citations · 1 hit paper
29 papers, 1.7k citations indexed

About

Melissa Paoloni is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Small Animals. According to data from OpenAlex, Melissa Paoloni has authored 29 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 13 papers in Genetics and 7 papers in Small Animals. Recurrent topics in Melissa Paoloni's work include Veterinary Oncology Research (14 papers), Virus-based gene therapy research (12 papers) and Infectious Diseases and Mycology (6 papers). Melissa Paoloni is often cited by papers focused on Veterinary Oncology Research (14 papers), Virus-based gene therapy research (12 papers) and Infectious Diseases and Mycology (6 papers). Melissa Paoloni collaborates with scholars based in United States, Japan and Italy. Melissa Paoloni's co-authors include Chand Khanna, Christina Mazcko, Ira K. Gordon, Susan E. Lana, Amy K. LeBlanc, Stephen J. Withrow, Sean Davis, Karin U. Sørenmo, Paul S. Meltzer and Stephen M. Hewitt and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and PLoS ONE.

In The Last Decade

Melissa Paoloni

29 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Translation of new cancer treatments from pet dogs to humans

2008 490 citations Melissa Paoloni, Chand Khanna Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Melissa Paoloni

Since Specialization

Citations

This map shows the geographic impact of Melissa Paoloni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa Paoloni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa Paoloni more than expected).

Fields of papers citing papers by Melissa Paoloni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa Paoloni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa Paoloni. The network helps show where Melissa Paoloni may publish in the future.

Co-authorship network of co-authors of Melissa Paoloni

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa Paoloni. A scholar is included among the top collaborators of Melissa Paoloni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa Paoloni. Melissa Paoloni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies. 2020 ·Journal of Clinical Oncology ·Johanna C. Bendell, Gulam A. Manji, Shubham Pant, Dominic W. Lai, (unknown), (unknown), Melissa Paoloni, William J. Grossman, Eileen M. O’Reilly	8
2	Abstract 858: Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL 2016 ·Cancer Research ·Denise M. Wolf, Christina Yau, Ashish Sanil, Lamorna Brown Swigart, Gillian L. Hirst, Meredith Buxton, Melissa Paoloni, (unknown), Olufunmilayo Olopade, Hope S. Rugo, (unknown), Fraser Symmans, Don Berry, Laura J. Esserman, Laura van ‘t Veer	2
3	Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma 2015 ·PLoS ONE ·Melissa Paoloni, Christina Mazcko, Kimberly A. Selting, Susan E. Lana, Lisa G. Barber, Jeffrey Phillips, Katherine A. Skorupski, David M. Vail, Heather Wilson‐Robles, Barbara J. Biller, Anne C. Avery, Matti Kiupel, Amy K. LeBlanc, (unknown), Beatrice Brunkhorst, Robert M. Tighe, Chand Khanna	40
4	Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. 2015 ·Journal of Clinical Oncology ·Debu Tripathy, A. Jo Chien, Nola M. Hylton, Meredith Buxton, (unknown), Anne M. Wallace, Andres Forero, Henry G. Kaplan, Rita Nanda, Kathy S. Albain, Stacy L. Moulder, Barbara Haley, Angela DeMichele, W. Fraser Symmans, Laura van ‘t Veer, Melissa Paoloni, Laura J. Esserman, Donald A. Berry, Douglas Yee	23
5	Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer 2015 ·PLoS ONE ·Deepika Dhawan, Melissa Paoloni, (unknown), Dipanwita Roy Choudhury, Bruce Α. Craig, José A. Ramos‐Vara, Noah M. Hahn, Patty L. Bonney, Chand Khanna, Deborah W. Knapp	45
6	Prospective Molecular Profiling of Canine Cancers Provides a Clinically Relevant Comparative Model for Evaluating Personalized Medicine (PMed) Trials 2014 ·PLoS ONE ·Melissa Paoloni, Craig P. Webb, Christina Mazcko, David Cherba, William P.D. Hendricks, Susan E. Lana, E. J. Ehrhart, (unknown), (unknown), (unknown), David M. Vail, Michael S. Henson, Michael O. Childress, Barbara E. Kitchell, Christopher Kingsley, Seungchan Kim, Mark W. Neff, Barbara J. Davis, Chand Khanna, Jeffrey M. Trent	26
7	Transforming the clinical trial process: The I-SPY 2 trial as a model for improving the efficiency of clinical trials and accelerating the drug-screening process. 2014 ·Journal of Clinical Oncology ·Meredith Buxton, (unknown), Angela DeMichele, Jane Perlmutter, Nola M. Hylton, Douglas Yee, Laura van’t Veer, W. Fraser Symmans, Michael Hogarth, Julia Lyandres, Sarah E. Davis, Susan Flynn, Melissa Paoloni, Donald A. Berry, Laura J. Esserman, (unknown)	2
8	A Compendium of Canine Normal Tissue Gene Expression 2011 ·PLoS ONE ·Joseph Briggs, Melissa Paoloni, Qingrong Chen, Xinyu Wen, Javed Khan, Chand Khanna	28
9	Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs 2010 ·PLoS ONE ·Melissa Paoloni, Christina Mazcko, Elizabeth Fox, Timothy M. Fan, Susan E. Lana, William C. Kisseberth, David M. Vail, (unknown), Tanasa S. Osborne, (unknown), Daniel L. Gustafson, Yunkai Yu, Liang Cao, Chand Khanna	48
10	The creation of the Comparative Oncology Trials Consortium Pharmacodynamic Core: Infrastructure for a virtual laboratory 2010 ·The Veterinary Journal ·Melissa Paoloni, Susan E. Lana, Douglas H. Thamm, Christina Mazcko, Stephen J. Withrow	9
11	COMPUTED TOMOGRAPHY CHARACTERISTICS OF CANINE TRACHEOBRONCHIAL LYMPH NODE METASTASIS 2010 ·Veterinary Radiology & Ultrasound ·Elizabeth A. Ballegeer, William M. Adams, Richard R. Dubielzig, Melissa Paoloni, Julia M. Klauer, Nicholas S. Keuler	64
12	Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFα to Cancer Vasculature 2009 ·PLoS ONE ·Melissa Paoloni, Anita Tandle, Christina Mazcko, (unknown), Stefan S. Kachala, Amy K. LeBlanc, Shelley J. Newman, David M. Vail, Carolyn J. Henry, Douglas H. Thamm, Karin U. Sørenmo, Amin Hajitou, Renata Pasqualini, Wadih Arap, Chand Khanna, Steven K. Libutti	88
13	The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway 2009 ·PLoS Medicine ·Ira K. Gordon, Melissa Paoloni, Christina Mazcko, Chand Khanna	167
14	Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression 2009 ·BMC Genomics ·Melissa Paoloni, Sean Davis, Susan E. Lana, Stephen J. Withrow, Luca Sangiorgi, Piero Picci, Stephen M. Hewitt, Timothy J. Triche, Paul S. Meltzer, Chand Khanna	210
15	Translation of new cancer treatments from pet dogs to humans breakdown → 2008 ·Nature reviews. Cancer ·Melissa Paoloni, Chand Khanna	490
16	CCNU for the Treatment of Dogs with Histiocytic Sarcoma 2007 ·Journal of Veterinary Internal Medicine ·Katherine A. Skorupski, Craig A. Clifford, Melissa Paoloni, Ana Lara‐Garcia, Lisa G. Barber, Michael S. Kent, Amy K. LeBlanc, (unknown), Elizabeth A. Mauldin, Frances S. Shofer, C. Guillermo Couto, Karin U. Sørenmo	107
17	CCNU for the Treatment of Dogs with Histiocytic Sarcoma 2007 ·Journal of Veterinary Internal Medicine ·Katherine A. Skorupski, Craig A. Clifford, Melissa Paoloni, Ana Lara‐Garcia, Lisa G. Barber, Michael S. Kent, Amy K. LeBlanc, (unknown), Elizabeth A. Mauldin, Frances S. Shofer, C. Guillermo Couto, Karin U. Sørenmo	94
18	Comparative Oncology Today 2007 ·Veterinary Clinics of North America Small Animal Practice ·Melissa Paoloni, Chand Khanna	87
19	Comparison of results of computed tomography and radiography with histopathologic findings in tracheobronchial lymph nodes in dogs with primary lung tumors: 14 cases (1999–2002) 2006 ·Journal of the American Veterinary Medical Association ·Melissa Paoloni, William M. Adams, Richard R. Dubielzig, Ilene D. Kurzman, David M. Vail, Robert J. Hardie	51
20	ULTRASONOGRAPHIC AND CLINICOPATHOLOGIC FINDINGS IN 21 DOGS WITH INTESTINAL ADENOCARCINOMA 2002 ·Veterinary Radiology & Ultrasound ·Melissa Paoloni, Dominique G. Penninck, Antony S. Moore	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact